Overview of SLC22A and SLCO families of drug uptake transporters in the context of cancer treatments

Current Drug Metabolism

Volumn 12, Issue 8, 2011, Pages 793-807

  Cutler, Murray J ^a,b   Choo, Edna F ^c  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Beatrice Hunter Cancer Research Institute   (Canada)

^c GENENTECH INC   (United States)

Author keywords

Anticancer drugs; Drug uptake transporters; Organic anion transporters; Organic anion transporting polypeptides; Organic cation carnitine transporters; Organic cationt ransporters

Indexed keywords

CYCLOPHOSPHAMIDE; IMATINIB; IRINOTECAN; MEMBRANE PROTEIN; MITOXANTRONE; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; ORGANIC CATION CARNITINE TRANSPORTER; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B3; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1C1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 2A1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 2B1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 3A1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 4A1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 4C1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 5A1; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 6A1; SOLUTE CARRIER PROTEIN 22A11; SOLUTE CARRIER PROTEIN 22A16; SOLUTE CARRIER PROTEIN 22A4; SOLUTE CARRIER PROTEIN 22A5; SOLUTE CARRIER PROTEIN 22A6; SOLUTE CARRIER PROTEIN 22A7; SOLUTE CARRIER PROTEIN 22A8; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER CELL CULTURE; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DRUG ACCUMULATION; DRUG UPTAKE; ENDOMETRIUM CANCER; MASS SPECTROMETRY; METASTASIS; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW;

EID: 80053553834     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798357060     Document Type: Review

References (204)

1. Bush, J.A.; Li, G. Cancer chemoresistance: the relationship betweenp53 and multidrug transporters. Int. J. Cancer, 2002, 98(3),323-330. (Pubitemid 34188673)
2. Desoize, B.; Jardillier, J. Multicellular resistance: a paradigm forclinical resistance? Crit Rev. Oncol. Hematol., 2000, 36(2-3), 193-207.
3. Donnenberg, V.S.; Donnenberg, A.D. Multiple drug resistance incancer revisited: the cancer stem cell hypothesis. J. Clin. Pharmacol.,2005, 45(8), 872-877. (Pubitemid 41060226)
4. Moscow, J.A.; Gong, M.; He, R.; Sgagias, M.K.; Dixon, K.H.;Anzick, S.L. et al. Isolation of a gene encoding a human reducedfolate carrier (RFC1) and analysis of its expression in transportdeficient,methotrexate-resistant human breast cancer cells. CancerRes., 1995, 55(17), 3790-3794.
5. Cole, S.P.; Bhardwaj, G.; Gerlach, J.H.; Mackie, J.E.; Grant, C.E.;Almquist, K.C. et al. Overexpression of a transporter gene in amultidrug-resistant human lung cancer cell line. Science, 1992,258(5088), 1650-1654. (Pubitemid 23012438)
6. Dano, K. Active outward transport of daunomycin in resistantEhrlich ascites tumor cells. Biochim. Biophys. Acta, 1973, 323(3),466-483.
7. Doyle, L.A.; Yang, W.; Abruzzo, L.V.; Krogmann, T.; Gao, Y.;Rishi, A.K. et al. A multidrug resistance transporter from humanMCF-7 breast cancer cells. Proc. Natl. Acad. Sci. U. S. A, 1998,95(26), 15665-15670. (Pubitemid 29018757)
8. Juliano, R.L. and Ling, V. A surface glycoprotein modulating drugpermeability in Chinese hamster ovary cell mutants. Biochim. Biophys.Acta, 1976, 455(1), 152-162.
9. McGrath, T. and Center, M.S. Mechanisms of multidrug resistancein HL60 cells: evidence that a surface membrane protein distinctfrom P-glycoprotein contributes to reduced cellular accumulationof drug. Cancer Res., 1988, 48(14), 3959-3963.
10. Szakacs, G.; Paterson, J.K.; Ludwig, J.A.; Booth-Genthe, C.; Gottesman,M.M. Targeting multidrug resistance in cancer. Nat. Rev.Drug Discov., 2006, 5(3), 219-234. (Pubitemid 43336035)
11. Haimeur, A.; Conseil, G.; Deeley, R.G.; Cole, S.P. The MRPrelatedand BCRP/ABCG2 multidrug resistance proteins: biology,substrate specificity and regulation. Curr. Drug Metab, 2004, 5(1),21-53. (Pubitemid 38294344)
12. Eckford, P.D. and Sharom, F.J. ABC efflux pump-based resistanceto chemotherapy drugs. Chem. Rev., 2009, 109(7), 2989-3011.
13. Gorboulev, V.; Ulzheimer, J.C.; Akhoundova, A.; Ulzheimer-Teuber, I.; Karbach, U.; Quester, S. et al. Cloning and characterizationof two human polyspecific organic cation transporters. DNACell Biol., 1997, 16(7), 871-881. (Pubitemid 27332696)
14. Lopez-Nieto, C.E.; You, G.; Bush, K.T.; Barros, E.J.; Beier, D.R.;Nigam, S.K. Molecular cloning and characterization of NKT, agene product related to the organic cation transporter family that isalmost exclusively expressed in the kidney. J. Biol. Chem., 1997,272(10), 6471-6478. (Pubitemid 27118127)
15. Kullak-Ublick, G.A.; Hagenbuch, B.; Stieger, B.; Schteingart,C.D.; Hofmann, A.F.; Wolkoff, A.W. et al. Molecular and functionalcharacterization of an organic anion transporting polypeptidecloned from human liver. Gastroenterology, 1995, 109(4), 1274-1282.
16. Hagenbuch, B. Drug uptake systems in liver and kidney: a historicperspective. Clin. Pharmacol. Ther., 2010, 87(1), 39-47.
17. Huang, Y.; Anderle, P.; Bussey, K.J.; Barbacioru, C.;Shankavaram, U.; Dai, Z. et al. Membrane transporters and channels:role of the transportome in cancer chemosensitivity andchemoresistance. Cancer Res., 2004, 64(12), 4294-4301. (Pubitemid 38802436)
18. Okabe, M.; Unno, M.; Harigae, H.; Kaku, M.; Okitsu, Y.; Sasaki,T. et al. Characterization of the organic cation transporterSLC22A16: a doxorubicin importer. Biochem. Biophys. Res. Commun.,2005, 333(3), 754-762. (Pubitemid 40854224)
19. Kamb, A. What's wrong with our cancer models? Nat. Rev. DrugDiscov., 2005, 4(2), 161-165. (Pubitemid 40277495)
20. Sugawara, M.; Okamoto, K.; Kadowaki, T.; Kusano, K.; Fukamizu,A.; Yoshimura, T. Expressions of cytochrome P450, UDPglucuronosyltranferase,and transporter genes in monolayer carcinomacells change in subcutaneous tumors grown as xenografts inimmunodeficient nude mice. Drug Metab Dispos., 2010, 38(3),526-533.
21. Koepsell, H.; Lips, K.; Volk, C. Polyspecific organic cation transporters:structure, function, physiological roles, and biopharmaceuticalimplications. Pharm. Res., 2007, 24(7), 1227-1251. (Pubitemid 46876495)
22. Grundemann, D.; Gorboulev, V.; Gambaryan, S.; Veyhl, M.; Koepsell,H. Drug excretion mediated by a new prototype of polyspecifictransporter. Nature, 1994, 372(6506), 549-552. (Pubitemid 24368536)
23. Breidert, T.; Spitzenberger, F.; Grundemann, D.; Schomig, E.Catecholamine transport by the organic cation transporter type 1(OCT1). Br. J. Pharmacol., 1998, 125(1), 218-224. (Pubitemid 28418775)
24. Kimura, H.; Takeda, M.; Narikawa, S.; Enomoto, A.; Ichida, K.;Endou, H. Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J.Pharmacol. Exp. Ther., 2002, 301(1), 293-298. (Pubitemid 34250307)
25. Motohashi, H.; Sakurai, Y.; Saito, H.; Masuda, S.; Urakami, Y.;Goto, M. et al. Gene expression levels and immunolocalization oforganic ion transporters in the human kidney. J. Am. Soc. Nephrol.,2002, 13(4), 866-874. (Pubitemid 34274082)
26. Eisenhofer, G. The role of neuronal and extraneuronal plasmamembrane transporters in the inactivation of peripheral catecholamines.Pharmacol. Ther., 2001, 91(1), 35-62. (Pubitemid 33055773)
27. Shang, T.; Uihlein, A.V.; Van Asten, J.; Kalyanaraman, B.; Hillard,C.J. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granuleneurons via organic cation transporter 3. J. Neurochem., 2003,85(2), 358-367. (Pubitemid 36438331)
28. Inazu, M.; Takeda, H.; Matsumiya, T. Expression and functionalcharacterization of the extraneuronal monoamine transporter innormal human astrocytes. J. Neurochem., 2003, 84(1), 43-52. (Pubitemid 36182064)
29. Busch, A.E.; Karbach, U.; Miska, D.; Gorboulev, V.; Akhoundova,A.; Volk, C. et al. Human neurons express the polyspecific cationtransporter hOCT2, which translocates monoamine neurotransmitters,amantadine, and memantine. Mol. Pharmacol., 1998, 54(2),342-352. (Pubitemid 28368824)
30. Wu, X.; Kekuda, R.; Huang, W.; Fei, Y.J.; Leibach, F.H.; Chen, J.et al. Identity of the organic cation transporter OCT3 as the extraneuronalmonoamine transporter (uptake2) and evidence for theexpression of the transporter in the brain. J. Biol. Chem., 1998,273(49), 32776-32786. (Pubitemid 28557664)
31. Kantarjian, H.M.; Cortes, J.E.; O'Brien, S.; Luthra, R.; Giles, F.;Verstovsek, S. et al. Long-term survival benefit and improvedcomplete cytogenetic and molecular response rates with imatinibmesylate in Philadelphia chromosome-positive chronic-phasechronic myeloid leukemia after failure of interferon-alpha. Blood,2004, 104(7), 1979-1988. (Pubitemid 39297846)
32. O'Brien, S.G.; Guilhot, F.; Larson, R.A.; Gathmann, I.; Baccarani,M.; Cervantes, F. et al. Imatinib compared with interferon and lowdosecytarabine for newly diagnosed chronic-phase chronic myeloidleukemia. N. Engl. J. Med., 2003, 348(11), 994-1004. (Pubitemid 36302244)
33. Thomas, J.; Wang, L.; Clark, R.E.; Pirmohamed, M. Active transportof imatinib into and out of cells: implications for drug resistance.Blood, 2004, 104(12), 3739-3745. (Pubitemid 39564452)
34. Crossman, L.C.; Druker, B.J.; Deininger, M.W.; Pirmohamed, M.;Wang, L.; Clark, R.E. hOCT 1 and resistance to imatinib. Blood,2005, 106(3), 1133-1134.
35. White, D.L.; Saunders, V.A.; Dang, P.; Engler, J.; Zannettino,A.C.; Cambareri, A.C. et al. OCT-1-mediated influx is a key determinantof the intracellular uptake of imatinib but not nilotinib(AMN107): reduced OCT-1 activity is the cause of low in vitrosensitivity to imatinib. Blood, 2006, 108(2), 697-704. (Pubitemid 44061372)
36. Hu, S.; Franke, R.M.; Filipski, K.K.; Hu, C.; Orwick, S.J.; deBruijn, E.A. et al. Interaction of imatinib with human organic ioncarriers. Clin. Cancer Res., 2008, 14(10), 3141-3148.
37. Wang, L.; Giannoudis, A.; Lane, S.; Williamson, P.; Pirmohamed,M.; Clark, R.E. Expression of the uptake drug transporter hOCT1 isan important clinical determinant of the response to imatinib inchronic myeloid leukemia. Clin. Pharmacol. Ther., 2008, 83(2),258-264.
38. White, D.L.; Dang, P.; Engler, J.; Frede, A.; Zrim, S.; Osborn, M.et al. Functional activity of the OCT-1 protein is predictive of longtermoutcome in patients with chronic-phase chronic myeloid leukemiatreated with imatinib. J. Clin. Oncol., 2010, 28(16), 2761-2767.
39. Kim, D.H.; Sriharsha, L.; Xu, W.; Kamel-Reid, S.; Liu, X.; Siminovitch,K. et al. Clinical relevance of a pharmacogenetic approachusing multiple candidate genes to predict response and resistance toimatinib therapy in chronic myeloid leukemia. Clin. Cancer Res.,2009, 15(14), 4750-4758.
40. Kerb, R.; Brinkmann, U.; Chatskaia, N.; Gorbunov, D.; Gorboulev,V.; Mornhinweg, E. et al. Identification of genetic variations of thehuman organic cation transporter hOCT1 and their functional consequences.Pharmacogenetics, 2002, 12(8), 591-595. (Pubitemid 36005667)
41. Shu, Y.; Leabman, M.K.; Feng, B.; Mangravite, L.M.; Huang,C.C.; Stryke, D. et al. Evolutionary conservation predicts functionof variants of the human organic cation transporter, OCT1. Proc.Natl. Acad. Sci. U. S. A, 2003, 100(10), 5902-5907. (Pubitemid 36576905)
42. Shu, Y.; Sheardown, S.A.; Brown, C.; Owen, R.P.; Zhang, S.;Castro, R.A. et al. Effect of genetic variation in the organic cationtransporter 1 (OCT1) on metformin action. J. Clin. Invest, 2007,117(5), 1422-1431. (Pubitemid 46718430)
43. Nies, A.T.; Koepsell, H.; Winter, S.; Burk, O.; Klein, K.; Kerb, R.et al. Expression of organic cation transporters OCT1 (SLC22A1)and OCT3 (SLC22A3) is affected by genetic factors and cholestasisin human liver. Hepatology, 2009, 50(4), 1227-1240.
44. Shu, Y.; Brown, C.; Castro, R.A.; Shi, R.J.; Lin, E.T.; Owen, R.P.et al. Effect of genetic variation in the organic cation transporter 1,OCT1, on metformin pharmacokinetics. Clin. Pharmacol. Ther.,2008, 83(2), 273-280.
45. Filipski, K.K.; Mathijssen, R.H.; Mikkelsen, T.S.; Schinkel, A.H.;Sparreboom, A. Contribution of organic cation transporter 2(OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol.Ther., 2009, 86(4), 396-402.
46. Galetti, M.; Alfieri, R.R.; Cavazzoni, A.; La Monica, S.; Bonelli,M.; Fumarola, C. et al. Functional characterization of gefitinib uptakein non-small cell lung cancer cell lines. Biochem. Pharmacol.,2010, 80(2), 179-187.
47. Morrow, C.J.; Ghattas, M.; Smith, C.; Bonisch, H.; Bryce, R.A.;Hickinson, D.M. et al. Src Family Kinase Inhibitor Saracatinib(AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cellsand Blocks Organic Cation Transporters. Cancer Res., 2010.
48. Raymond, E.; Faivre, S.; Chaney, S.; Woynarowski, J.; Cvitkovic,E. Cellular and molecular pharmacology of oxaliplatin. Mol. CancerTher., 2002, 1(3), 227-235.
49. Raymond, E.; Chaney, S.G.; Taamma, A.; Cvitkovic, E. Oxaliplatin:a review of preclinical and clinical studies. Ann. Oncol.,1998, 9(10), 1053-1071. (Pubitemid 28518143)
50. Rixe, O.; Ortuzar, W.; Alvarez, M.; Parker, R.; Reed, E.; Paull, K.et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum ofactivity in drug-resistant cell lines and in the cell lines of the NationalCancer Institute's Anticancer Drug Screen panel. Biochem.Pharmacol., 1996, 52(12), 1855-1865. (Pubitemid 26419675)
51. Hussain, S.A.; Ma, Y.T.; Cullen, M.H. Management of metastaticgerm cell tumors. Expert. Rev. Anticancer Ther., 2008, 8(5), 771-784.
52. Gallagher, D.J.; Milowsky, M.I.; Bajorin, D.F. Advanced bladdercancer: status of first-line chemotherapy and the search for activeagents in the second-line setting. Cancer, 2008, 113(6), 1284-1293.
53. Omura, G.A. Progress in gynecologic cancer research: the GynecologicOncology Group experience. Semin. Oncol., 2008, 35(5),507-521.
54. Fischer, B. and Arcaro, A. Current status of clinical trials for smallcell lung cancer. Rev. Recent Clin. Trials, 2008, 3(1), 40-61. (Pubitemid 351267025)
55. Lustberg, M.B. and Edelman, M.J. Optimal duration of chemotherapyin advanced non-small cell lung cancer. Curr. Treat. Options.Oncol., 2007, 8(1), 38-46.
56. Yang, E.S.; Murphy, B.M.; Chung, C.H.; Netterville, J.L.; Burkey,B.B.; Gilbert, J. et al. Evolution of clinical trials in head and neckcancer. Crit Rev. Oncol. Hematol., 2009, 71(1), 29-42.
57. Howell, S.B.; Safaei, R.; Larson, C.A.; Sailor, M.J. Copper transportersand the cellular pharmacology of the platinum-containingcancer drugs. Mol. Pharmacol., 2010, 77(6), 887-894.
58. Burger, H.; Zoumaro-Djayoon, A.; Boersma, A.W.; Helleman, J.;Berns, E.M.; Mathijssen, R.H. et al. Differential transport of platinumcompounds by the human organic cation transporter hOCT2(hSLC22A2). Br. J. Pharmacol., 2010, 159(4), 898-908.
59. Yokoo, S.; Masuda, S.; Yonezawa, A.; Terada, T.; Katsura, T.;Inui, K. Significance of organic cation transporter 3 (SLC22A3)expression for the cytotoxic effect of oxaliplatin in colorectal cancer.Drug Metab Dispos., 2008, 36(11), 2299-2306.
60. Yonezawa, A.; Masuda, S.; Yokoo, S.; Katsura, T.; Inui, K. Cisplatinand oxaliplatin, but not carboplatin and nedaplatin, are substratesfor human organic cation transporters (SLC22A1-3 andmultidrug and toxin extrusion family). J. Pharmacol. Exp. Ther.,2006, 319(2), 879-886.
61. Zhang, S.; Lovejoy, K.S.; Shima, J.E.; Lagpacan, L.L.; Shu, Y.;Lapuk, A. et al. Organic cation transporters are determinants of oxaliplatincytotoxicity. Cancer Res., 2006, 66(17), 8847-8857. (Pubitemid 44449203)
62. Ballestero, M.R.; Monte, M.J.; Briz, O.; Jimenez, F.; Gonzalez-SanMartin, F.; Marin, J.J. Expression of transporters potentially involvedin the targeting of cytostatic bile acid derivatives to coloncancer and polyps. Biochem. Pharmacol., 2006, 72(6), 729-738. (Pubitemid 44233549)
63. Briz, O.; Serrano, M.A.; Rebollo, N.; Hagenbuch, B.; Meier, P.J.;Koepsell, H. et al. Carriers involved in targeting the cytostatic bileacid-cisplatin derivatives cis-diammine-chloro-cholylglycinate platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II)toward liver cells. Mol. Pharmacol., 2002, 61(4), 853-860. (Pubitemid 34273165)
64. Lovejoy, K.S.; Todd, R.C.; Zhang, S.; McCormick, M.S.;D'Aquino, J.A.; Reardon, J.T. et al. cis-Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake,structure, function, and prospects. Proc. Natl. Acad. Sci. U. S.A, 2008, 105(26), 8902-8907.
65. More, S.S.; Li, S.; Yee, S.W.; Chen, L.; Xu, Z.; Jablons, D.M. et al.Organic cation transporters modulate the uptake and cytotoxicity ofpicoplatin, a third-generation platinum analogue. Mol. CancerTher., 2010, 9(4), 1058-1069.
66. Franke, R.M.; Kosloske, A.M.; Lancaster, C.S.; Filipski, K.K.; Hu,C.; Zolk, O. et al. Influence of Oct1/Oct2-deficiency on cisplatininducedchanges in urinary N-acetyl-beta-D-glucosaminidase. Clin.Cancer Res., 2010, 16(16), 4198-4206.
67. Shnitsar, V.; Eckardt, R.; Gupta, S.; Grottker, J.; Muller, G.A.;Koepsell, H. et al. Expression of human organic cation transporter3 in kidney carcinoma cell lines increases chemosensitivity to melphalan,irinotecan, and vincristine. Cancer Res., 2009, 69(4), 1494-1501.
68. Holzer, A.K.; Manorek, G.H.; Howell, S.B. Contribution of themajor copper influx transporter CTR1 to the cellular accumulationof cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol., 2006,70(4), 1390-1394. (Pubitemid 44435991)
69. Larson, C.A.; Blair, B.G.; Safaei, R.; Howell, S.B. The role of themammalian copper transporter 1 in the cellular accumulation ofplatinum-based drugs. Mol. Pharmacol., 2009, 75(2), 324-330.
70. Ishida, S.; McCormick, F.; Smith-McCune, K.; Hanahan, D. Enhancingtumor-specific uptake of the anticancer drug cisplatin witha copper chelator. Cancer Cell, 2010, 17(6), 574-583.
71. Camano, S.; Lazaro, A.; Moreno-Gordaliza, E.; Torres, A.M.; deLucas, C.; Humanes, B. et al. Cilastatin attenuates cisplatininducedproximal tubular cell damage. J. Pharmacol. Exp. Ther.,2010, 334(2), 419-429.
72. More, S.S.; Akil, O.; Ianculescu, A.G.; Geier, E.G.; Lustig, L.R.;Giacomini, K.M. Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J. Neurosci., 2010, 30(28), 9500-9509.
73. Pabla, N. and Dong, Z. Cisplatin nephrotoxicity: mechanisms andrenoprotective strategies. Kidney Int., 2008, 73(9), 994-1007. (Pubitemid 351543900)
74. Blair, B.G.; Larson, C.A.; Safaei, R.; Howell, S.B. Copper transporter2 regulates the cellular accumulation and cytotoxicity ofCisplatin and Carboplatin. Clin. Cancer Res., 2009, 15(13), 4312-4321.
75. Blair, B.G.; Larson, C.A.; Adams, P.L.; Abada, P.B.; Safaei, R.;Howell, S.B. Regulation of copper transporter 2 expression by copperand cisplatin in human ovarian carcinoma cells. Mol. Pharmacol.,2010, 77(6), 912-921.
76. Blair, B.G.; Larson, C.A.; Adams, P.L.; Abada, P.B.; Pesce, C.E.;Safaei, R. et al. Copper transporter 2 regulates endocytosis andcontrols tumor growth and sensitivity to cisplatin in vivo. Mol.Pharmacol., 2011, 79(1), 157-166.
77. Enomoto, A.; Wempe, M.F.; Tsuchida, H.; Shin, H.J.; Cha, S.H.;Anzai, N. et al. Molecular identification of a novel carnitine transporterspecific to human testis. Insights into the mechanism of carnitinerecognition. J. Biol. Chem., 2002, 277(39), 36262-36271.
78. Gong, S.; Lu, X.; Xu, Y.; Swiderski, C.F.; Jordan, C.T.; Moscow,J.A. Identification of OCT6 as a novel organic cation transporterpreferentially expressed in hematopoietic cells and leukemias. Exp.Hematol., 2002, 30(10), 1162-1169.
79. Aouida, M.; Poulin, R.; Ramotar, D. The human carnitine transporterSLC22A16 mediates high affinity uptake of the anticancerpolyamine analogue bleomycin-A5. J. Biol. Chem., 2010, 285(9),6275-6284.
80. Sato, N.; Ito, K.; Onogawa, T.; Akahira, J.; Unno, M.; Abe, T. et al.Expression of organic cation transporter SLC22A16 in human endometria.Int. J. Gynecol. Pathol., 2007, 26(1), 53-60. (Pubitemid 46036959)
81. Ota, K.; Ito, K.; Akahira, J.; Sato, N.; Onogawa, T.; Moriya, T. etal. Expression of organic cation transporter SLC22A16 in humanepithelial ovarian cancer: a possible role of the adriamycin importer.Int. J. Gynecol. Pathol., 2007, 26(3), 334-340. (Pubitemid 46986072)
82. Ayoub, J.; Audet-Lapointe, P.; Methot, Y.; Hanley, J.; Beaulieu,R.; Chemaly, R. et al. Efficacy of sequential cyclical hormonaltherapy in endometrial cancer and its correlation with steroid hormonereceptor status. Gynecol. Oncol., 1988, 31(2), 327-337.
83. Lal, S.; Wong, Z.W.; Jada, S.R.; Xiang, X.; Chen, S., X; Ang, P.C.et al. Novel SLC22A16 polymorphisms and influence on doxorubicinpharmacokinetics in Asian breast cancer patients. Pharmacogenomics.,2007, 8(6), 567-575. (Pubitemid 46939582)
84. Bray, J.; Sludden, J.; Griffin, M.J.; Cole, M.; Verrill, M.; Jamieson,D. et al. Influence of pharmacogenetics on response and toxicity inbreast cancer patients treated with doxorubicin and cyclophosphamide.Br. J. Cancer, 2010, 102(6), 1003-1009.
85. Grube, M.; Meyer zu Schwabedissen, H.E.; Prager, D.; Haney, J.;Moritz, K.U.; Meissner, K. et al. Uptake of cardiovascular drugsinto the human heart: expression, regulation, and function of thecarnitine transporter OCTN2 (SLC22A5). Circulation, 2006,113(8), 1114-1122.
86. Okabe, M.; Szakacs, G.; Reimers, M.A.; Suzuki, T.; Hall, M.D.;Abe, T. et al. Profiling SLCO and SLC22 genes in the NCI-60 cancercell lines to identify drug uptake transporters. Mol. CancerTher., 2008, 7(9), 3081-3091.
87. Monks, N.R.; Liu, S.; Xu, Y.; Yu, H.; Bendelow, A.S.; Moscow,J.A. Potent cytotoxicity of the phosphatase inhibitor microcystinLR and microcystin analogues in OAT. Mol. Cancer Ther., 2007,6(2), 587-598. (Pubitemid 46332461)
88. Hu, S.; Chen, Z.; Franke, R.; Orwick, S.; Zhao, M.; Rudek, M.A. etal. Interaction of the multikinase inhibitors sorafenib and sunitinibwith solute carriers and ATP-binding cassette transporters. Clin.Cancer Res., 2009, 15(19), 6062-6069.
89. Lenihan, D.J. Tyrosine kinase inhibitors: can promising new therapyassociated with cardiac toxicity strengthen the concept ofteamwork? J. Clin. Oncol., 2008, 26(32), 5154-5155.
90. Mann, D.L. Targeted cancer therapeutics: the heartbreak of success.Nat. Med., 2006, 12(8), 881-882. (Pubitemid 44175133)
91. Ciarimboli, G. and Schlatter, E. Regulation of organic cation transport.Pflugers Arch., 2005, 449(5), 423-441. (Pubitemid 40238877)
92. Klaassen, C.D. and Aleksunes, L.M. Xenobiotic, bile acid, andcholesterol transporters: function and regulation. Pharmacol. Rev.,2010, 62(1), 1-96.
93. Sekine, T.; Watanabe, N.; Hosoyamada, M.; Kanai, Y.; Endou, H.Expression cloning and characterization of a novel multispecificorganic anion transporter. J. Biol. Chem., 1997, 272(30), 18526-18529. (Pubitemid 27318187)
94. Sweet, D.H.; Wolff, N.A.; Pritchard, J.B. Expression cloning andcharacterization of ROAT1. The basolateral organic anion transporterin rat kidney. J. Biol. Chem., 1997, 272(48), 30088-30095. (Pubitemid 27512205)
95. Ahn, S.Y. and Nigam, S.K. Toward a systems level understandingof organic anion and other multispecific drug transporters: a remotesensing and signaling hypothesis. Mol. Pharmacol., 2009, 76(3),481-490.
96. Eraly, S.A.; Bush, K.T.; Sampogna, R.V.; Bhatnagar, V.; Nigam,S.K. The molecular pharmacology of organic anion transporters:from DNA to FDA? Mol. Pharmacol., 2004, 65(3), 479-487. (Pubitemid 38264013)
97. Sweet, D.H. Organic anion transporter (Slc22a) family members asmediators of toxicity. Toxicol. Appl. Pharmacol., 2005, 204(3),198-215. (Pubitemid 40545228)
98. Bakhiya, A.; Bahn, A.; Burckhardt, G.; Wolff, N. Human organicanion transporter 3 (hOAT3) can operate as an exchanger and mediatesecretory urate flux. Cell Physiol Biochem., 2003, 13(5), 249-256. (Pubitemid 37356730)
99. Enomoto, A.; Kimura, H.; Chairoungdua, A.; Shigeta, Y.; Jutabha,P.; Cha, S.H. et al. Molecular identification of a renal urate anionexchanger that regulates blood urate levels. Nature, 2002,417(6887), 447-452. (Pubitemid 34563537)
100. Hagos, Y.; Stein, D.; Ugele, B.; Burckhardt, G.; Bahn, A. Humanrenal organic anion transporter 4 operates as an asymmetric uratetransporter. J. Am. Soc. Nephrol., 2007, 18(2), 430-439. (Pubitemid 46193309)
101. Ichida, K.; Hosoyamada, M.; Kimura, H.; Takeda, M.; Utsunomiya,Y.; Hosoya, T. et al. Urate transport via human PAH transporterhOAT1 and its gene structure. Kidney Int., 2003, 63(1), 143-155. (Pubitemid 35463915)
102. Islam, R.; Anzai, N.; Ahmed, N.; Ellapan, B.; Jin, C.J.; Srivastava,S. et al. Mouse organic anion transporter 2 (mOat2) mediates thetransport of short chain fatty acid propionate. J. Pharmacol. Sci.,2008, 106(3), 525-528. (Pubitemid 351468607)
103. Fleck, C.; Bachner, B.; Gockeritz, S.; Karge, E.; Strohm, U.; Schubert,J. Ex vivo stimulation of renal tubular p-aminohippuratetransport by dexamethasone and triiodothyronine in human renalcell carcinoma. Urol. Res., 2000, 28(6), 383-390. (Pubitemid 32039608)
104. Fleck, C.; Gockeritz, S.; Schubert, J. Tubular PAH transport capacityin human kidney tissue and in renal cell carcinoma: correlate with various clinical and morphological parameters of the tumor.Urol. Res., 1997, 25(3), 167-171. (Pubitemid 27252792)
105. Asif, A.R.; Steffgen, J.; Metten, M.; Grunewald, R.W.; Muller,G.A.; Bahn, A. et al. Presence of organic anion transporters 3(OAT3) and 4 (OAT4) in human adrenocortical cells. PflugersArch., 2005, 450(2), 88-95. (Pubitemid 40674733)
106. Sekine, T.; Miyazaki, H.; Endou, H. Molecular physiology of renalorganic anion transporters. Am. J. Physiol Renal Physiol, 2006,290(2), F251-F261. (Pubitemid 43724979)
107. Kobayashi, Y.; Ohshiro, N.; Sakai, R.; Ohbayashi, M.; Kohyama,N.; Yamamoto, T. Transport mechanism and substrate specificityof human organic anion transporter 2 (hOat2 [SLC22A7]). J.Pharm. Pharmacol., 2005, 57(5), 573-578. (Pubitemid 40562396)
108. Kobayashi, Y.; Ohshiro, N.; Tsuchiya, A.; Kohyama, N.; Ohbayashi,M.; Yamamoto, T. Renal transport of organic compounds mediatedby mouse organic anion transporter 3 (mOat3): further substratespecificity of mOat3. Drug Metab Dispos., 2004, 32(5), 479-483. (Pubitemid 38535024)
109. Mori, S.; Ohtsuki, S.; Takanaga, H.; Kikkawa, T.; Kang, Y.S.;Terasaki, T. Organic anion transporter 3 is involved in the brain-tobloodefflux transport of thiopurine nucleobase analogs. J. Neurochem.,2004, 90(4), 931-941. (Pubitemid 39099975)
110. Cha, S.H.; Sekine, T.; Fukushima, J.I.; Kanai, Y.; Kobayashi, Y.;Goya, T. et al. Identification and characterization of human organicanion transporter 3 expressing predominantly in the kidney. Mol.Pharmacol., 2001, 59(5), 1277-1286. (Pubitemid 32385197)
111. Sun, W.; Wu, R.R.; van Poelje, P.D.; Erion, M.D. Isolation of afamily of organic anion transporters from human liver and kidney.Biochem. Biophys. Res. Commun., 2001, 283(2), 417-422. (Pubitemid 32924708)
112. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Hosoyamada,M.; Cha, S.H. et al. Characterization of methotrexate transportand its drug interactions with human organic anion transporters.J. Pharmacol. Exp. Ther., 2002, 302(2), 666-671. (Pubitemid 34787234)
113. Shen, D.D. and Azarnoff, D.L. Clinical pharmacokinetics ofmethotrexate. Clin. Pharmacokinet., 1978, 3(1), 1-13.
114. Basin, K.S.; Escalante, A.; Beardmore, T.D. Severe pancytopeniain a patient taking low dose methotrexate and probenecid. J. Rheumatol.,1991, 18(4), 609-610.
115. Ellison, N.M. and Servi, R.J. Acute renal failure and death followingsequential intermediate-dose methotrexate and 5-FU: a possibleadverse effect due to concomitant indomethacin administration.Cancer Treat. Rep., 1985, 69(3), 342-343. (Pubitemid 15080828)
116. Frenia, M.L. and Long, K.S. Methotrexate and nonsteroidal antiinflammatorydrug interactions. Ann. Pharmacother., 1992, 26(2),234-237.
117. Thyss, A.; Milano, G.; Kubar, J.; Namer, M.; Schneider, M. Clinicaland pharmacokinetic evidence of a life-threatening interactionbetween methotrexate and ketoprofen. Lancet, 1986, 1(8475), 256-258. (Pubitemid 16132863)
118. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Kobayashi,Y.; Yamamoto, T. et al. Human organic anion transporters and humanorganic cation transporters mediate renal antiviral transport. J.Pharmacol. Exp. Ther., 2002, 300(3), 918-924. (Pubitemid 34164996)
119. Zhao, R.; Qiu, A.; Tsai, E.; Jansen, M.; Akabas, M.H.; Goldman,I.D. The proton-coupled folate transporter: impact on pemetrexedtransport and on antifolates activities compared with the reducedfolate carrier. Mol. Pharmacol., 2008, 74(3), 854-862.
120. VanWert, A.L. and Sweet, D.H. Impaired clearance ofmethotrexate in organic anion transporter 3 (Slc22a8) knockoutmice: a gender specific impact of reduced folates. Pharm. Res.,2008, 25(2), 453-462. (Pubitemid 351257979)
121. Sweet, D.H.; Miller, D.S.; Pritchard, J.B.; Fujiwara, Y.; Beier,D.R.; Nigam, S.K. Impaired organic anion transport in kidney andchoroid plexus of organic anion transporter 3 (Oat3 (Slc22a8))knockout mice. J. Biol. Chem., 2002, 277(30), 26934-26943. (Pubitemid 34951703)
122. Hagenbuch, B. and Gui, C. Xenobiotic transporters of the humanorganic anion transporting polypeptides (OATP) family. Xenobiotica,2008, 38(7-8), 778-801.
123. Abe, T.; Unno, M.; Onogawa, T.; Tokui, T.; Kondo, T.N.; Nakagomi,R. et al. LST-2, a human liver-specific organic anion transporter,determines methotrexate sensitivity in gastrointestinal cancers.Gastroenterology, 2001, 120(7), 1689-1699. (Pubitemid 32523487)
124. Ancona, N.; Maglietta, R.; Piepoli, A.; D'Addabbo, A.; Cotugno,R.; Savino, M. et al. On the statistical assessment of classifiers usingDNA microarray data. BMC. Bioinformatics., 2006, 7, 387.
125. Lee, W.; Belkhiri, A.; Lockhart, A.C.; Merchant, N.; Glaeser, H.;Harris, E.I. et al. Overexpression of OATP1B3 confers apoptoticresistance in colon cancer. Cancer Res., 2008, 68(24), 10315-10323.
126. Nozawa, T.; Minami, H.; Sugiura, S.; Tsuji, A.; Tamai, I. Role oforganic anion transporter OATP1B1 (OATP-C) in hepatic uptakeof irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotidepolymorphisms. Drug Metab Dispos., 2005, 33(3), 434-439. (Pubitemid 40279945)
127. Oostendorp, R.L.; van de, S.E.; van der Kruijssen, C.M.; Beijnen,J.H.; Kenworthy, K.E.; Schinkel, A.H. et al. Organic aniontransportingpolypeptide 1B1 mediates transport of Gimatecan andBNP1350 and can be inhibited by several classic ATP-binding cassette(ABC) B1 and/or ABCG2 inhibitors. Drug Metab Dispos.,2009, 37(4), 917-923.
128. Yamaguchi, H.; Kobayashi, M.; Okada, M.; Takeuchi, T.; Unno,M.; Abe, T. et al. Rapid screening of antineoplastic candidates forthe human organic anion transporter OATP1B3 substrates usingfluorescent probes. Cancer Lett., 2008, 260(1-2), 163-169.
129. Takasuna, K.; Hagiwara, T.; Hirohashi, M.; Kato, M.; Nomura, M.;Nagai, E. et al. Involvement of beta-glucuronidase in intestinal microflorain the intestinal toxicity of the antitumor camptothecin derivativeirinotecan hydrochloride (CPT-11) in rats. Cancer Res.,1996, 56(16), 3752-3757. (Pubitemid 26272025)
130. Cui, Y.; Konig, J.; Nies, A.T.; Pfannschmidt, M.; Hergt, M.;Franke, W.W. et al. Detection of the human organic anion transportersSLC21A6 (OATP2) and SLC21A8 (OATP8) in liver andhepatocellular carcinoma. Lab Invest, 2003, 83(4), 527-538. (Pubitemid 36457707)
131. Narita, M.; Hatano, E.; Arizono, S.; Miyagawa-Hayashino, A.;Isoda, H.; Kitamura, K. et al. Expression of OATP1B3 determinesuptake of Gd-EOB-DTPA in hepatocellular carcinoma. J. Gastroenterol.,2009, 44(7), 793-798.
132. Vavricka, S.R.; Jung, D.; Fried, M.; Grutzner, U.; Meier, P.J.;Kullak-Ublick, G.A. The human organic anion transporting polypeptide8 (SLCO1B3) gene is transcriptionally repressed by hepatocytenuclear factor 3beta in hepatocellular carcinoma. J. Hepatol.,2004, 40(2), 212-218. (Pubitemid 38115824)
133. Vander, B.S.; Libbrecht, L.; Blokzijl, H.; Faber, K.N.; Moshage,H.; Aerts, R. et al. Diagnostic and pathogenetic implications of theexpression of hepatic transporters in focal lesions occurring innormal liver. J. Pathol., 2005, 207(4), 471-482. (Pubitemid 43025696)
134. Smith, N.F.; Acharya, M.R.; Desai, N.; Figg, W.D.; Sparreboom,A. Identification of OATP1B3 as a high-affinity hepatocellulartransporter of paclitaxel. Cancer Biol. Ther., 2005, 4(8), 815-818.
135. Smith, N.F.; Marsh, S.; Scott-Horton, T.J.; Hamada, A.; Mielke, S.;Mross, K. et al. Variants in the SLCO1B3 gene: interethnic distributionand association with paclitaxel pharmacokinetics. Clin.Pharmacol. Ther., 2007, 81(1), 76-82. (Pubitemid 46050869)
136. van de, S.E.; van Esch, A.; Wagenaar, E.; van der Kruijssen, C.M.;van Tellingen, O.; Kenworthy, K.E. et al. High impact ofOatp1a/1b transporters on in vivo disposition of the hydrophobicanticancer drug paclitaxel. Clin. Cancer Res., 2011, 17(2), 294-301.
137. van de, S.E.; Wagenaar, E.; van der Kruijssen, C.M.; Burggraaff,J.E.; de Waart, D.R.; Elferink, R.P. et al. Organic anion transportingpolypeptide 1a/1b-knockout mice provide insights into hepatichandling of bilirubin, bile
138. van de, S.E.; van der Kruijssen, C.M.; Wagenaar, E.; Burggraaff,J.E.; Mesman, E.; Kenworthy, K.E. et al. Methotrexate pharmacokineticsin transgenic mice with liver-specific expression of humanorganic anion-transporting polypeptide 1B1 (SLCO1B1).Drug Metab Dispos., 2009, 37(2), 277-281.
139. Meyer zu Schwabedissen, H.E.; Tirona, R.G.; Yip, C.S.; Ho, R.H.;Kim, R.B. Interplay between the nuclear receptor pregnane X receptorand the uptake transporter organic anion transporter polypeptide1A2 selectively enhances estrogen effects in breast cancer.Cancer Res., 2008, 68(22), 9338-9347.
140. Miki, Y.; Suzuki, T.; Kitada, K.; Yabuki, N.; Shibuya, R.; Moriya,T. et al. Expression of the steroid and xenobiotic receptor and itspossible target gene, organic anion transporting polypeptide-A, inhuman breast carcinoma. Cancer Res., 2006, 66(1), 535-542. (Pubitemid 43168338)
141. Muto, M.; Onogawa, T.; Suzuki, T.; Ishida, T.; Rikiyama, T.; Katayose,Y. et al. Human liver-specific organic anion transporter-2 isa potent prognostic factor for human breast carcinoma. Cancer Sci.,2007, 98(10), 1570-1576. (Pubitemid 47308452)
142. Wlcek, K.; Svoboda, M.; Thalhammer, T.; Sellner, F.; Krupitza,G.; Jaeger, W. Altered expression of organic anion transporterpolypeptide (OATP) genes in human breast carcinoma. CancerBiol. Ther., 2008, 7(9), 1450-1455.
143. Al Sarakbi, W.; Mokbel, R.; Salhab, M.; Jiang, W.G.; Reed, M.J.;Mokbel, K. The role of STS and OATP-B mRNA expression inpredicting the clinical outcome in human breast cancer. AnticancerRes., 2006, 26(6C), 4985-4990. (Pubitemid 46032147)
144. Kindla, J.; Rau, T.T.; Jung, R.; Fasching, P.A.; Strick, R.; Stoehr,R. et al. Expression and localization of the uptake transportersOATP2B1, OATP3A1 and OATP5A1 in non-malignant and malignantbreast tissue. Cancer Biol. Ther., 2011, 11(6), 584-591.
145. Maeda, T.; Irokawa, M.; Arakawa, H.; Kuraoka, E.; Nozawa, T.;Tateoka, R. et al. Uptake transporter organic anion transportingpolypeptide 1B3 contributes to the growth of estrogen-dependentbreast cancer. J. Steroid Biochem. Mol. Biol., 2010.
146. Nozawa, T.; Suzuki, M.; Yabuuchi, H.; Irokawa, M.; Tsuji, A.;Tamai, I. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells.Pharm. Res., 2005, 22(10), 1634-1641. (Pubitemid 41355902)
147. Wright, J.L.; Kwon, E.M.; Ostrander, E.A.; Montgomery, R.B.;Lin, D.W.; Vessella, R. et al. Expression of SLCO Transport Genesin Castration-Resistant Prostate Cancer and Impact of GeneticVariation in SLCO1B3 and SLCO2B1 on Prostate Cancer Outcomes.Cancer Epidemiol. Biomarkers Prev., 2011, 20(4), 619-627.
148. Jacobs, M.N.; Nolan, G.T.; Hood, S.R. Lignans, bacteriocides andorganochlorine compounds activate the human pregnane X receptor(PXR). Toxicol. Appl. Pharmacol., 2005, 209(2), 123-133. (Pubitemid 41594637)
149. Mnif, W.; Pascussi, J.M.; Pillon, A.; Escande, A.; Bartegi, A.;Nicolas, J.C. et al. Estrogens and antiestrogens activate hPXR.Toxicol. Lett., 2007, 170(1), 19-29. (Pubitemid 46509749)
150. Deeken, J.F. and Loscher, W. The blood-brain barrier and cancer:transporters, treatment, and Trojan horses. Clin. Cancer Res., 2007,13(6), 1663-1674. (Pubitemid 46952931)
151. Bronger, H.; Konig, J.; Kopplow, K.; Steiner, H.H.; Ahmadi, R.;Herold-Mende, C. et al. ABCC drug efflux pumps and organic anionuptake transporters in human gliomas and the blood-tumor barrier.Cancer Res., 2005, 65(24), 11419-11428. (Pubitemid 41821699)
152. Badagnani, I.; Castro, R.A.; Taylor, T.R.; Brett, C.M.; Huang,C.C.; Stryke, D. et al. Interaction of methotrexate with organicaniontransporting polypeptide 1A2 and its genetic variants. J.Pharmacol. Exp. Ther., 2006, 318(2), 521-529. (Pubitemid 44061225)
153. Mikkaichi, T.; Suzuki, T.; Onogawa, T.; Tanemoto, M.; Mizutamari,H.; Okada, M. et al. Isolation and characterization of a digoxintransporter and its rat homologue expressed in the kidney.Proc. Natl. Acad. Sci. U. S. A, 2004, 101(10), 3569-3574. (Pubitemid 38338236)
154. Sasaki, M.; Suzuki, H.; Aoki, J.; Ito, K.; Meier, P.J.; Sugiyama, Y.Prediction of in vivo biliary clearance from the in vitro transcellulartransport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic aniontransporting polypeptide 4 and multidrug resistance associatedprotein 2. Mol. Pharmacol., 2004, 66(3), 450-459. (Pubitemid 39329243)
155. Keshishian, H.; Addona, T.; Burgess, M.; Kuhn, E.; Carr, S.A.Quantitative, multiplexed assays for low abundance proteins inplasma by targeted mass spectrometry and stable isotope dilution.Mol. Cell Proteomics., 2007, 6(12), 2212-2229.
156. Melanson, J.E.; Avery, S.L.; Pinto, D.M. High-coverage quantitativeproteomics using amine-specific isotopic labeling. Proteomics.,2006, 6(16), 4466-4474. (Pubitemid 44336964)
157. Ross, P.L.; Huang, Y.N.; Marchese, J.N.; Williamson, B.; Parker,K.; Hattan, S. et al. Multiplexed protein quantitation in Saccharomycescerevisiae using amine-reactive isobaric tagging reagents.Mol. Cell Proteomics., 2004, 3(12), 1154-1169.
158. Aleksunes, L.M.; Augustine, L.M.; Scheffer, G.L.; Cherrington,N.J.; Manautou, J.E. Renal xenobiotic transporters are differentiallyexpressed in mice following cisplatin treatment. Toxicology, 2008,250(2-3), 82-88.
159. Shibayama, Y.; Ushinohama, K.; Ikeda, R.; Yoshikawa, Y.; Motoya,T.; Takeda, Y. et al. Effect of methotrexate treatment on expressionlevels of multidrug resistance protein 2, breast cancer resistanceprotein and organic anion transporters Oat1, Oat2 and Oat3in rats. Cancer Sci., 2006, 97(11), 1260-1266. (Pubitemid 44430654)
160. Khan, M.T. Predictions of the ADMET properties of candidatedrug molecules utilizing different QSAR/QSPR modelling approaches.Curr. Drug Metab, 2010, 11(4), 285-295.
161. Bayer, M.; Kuci, Z.; Schomig, E.; Grundemann, D.; Dittmann, H.;Handgretinger, R. et al. Uptake of mIBG and catecholamines innoradrenaline- and organic cation transporter-expressing cells: potentialuse of corticosterone for a preferred uptake in neuroblastoma-and pheochromocytoma cells. Nucl. Med. Biol., 2009, 36(3),287-294.
162. Alcorn, J.; Lu, X.; Moscow, J.A.; McNamara, P.J. Transporter geneexpression in lactating and nonlactating human mammary epithelialcells using real-time reverse transcription-polymerase chain reaction.J. Pharmacol. Exp. Ther., 2002, 303(2), 487-496. (Pubitemid 35231217)
163. Kwok, B.; Yamauchi, A.; Rajesan, R.; Chan, L.; Dhillon, U.; Gao,W. et al. Carnitine/xenobiotics transporters in the human mammarygland epithelia, MCF12A. Am. J. Physiol Regul. Integr. CompPhysiol, 2006, 290(3), R793-R802.
164. Verhaagh, S.; Schweifer, N.; Barlow, D.P.; Zwart, R. Cloning ofthe mouse and human solute carrier 22a3 (Slc22a3/SLC22A3)identifies a conserved cluster of three organic cation transporters onmouse chromosome 17 and human 6q26-q27. Genomics, 1999,55(2), 209-218. (Pubitemid 29093516)
165. Jung, N.; Lehmann, C.; Rubbert, A.; Knispel, M.; Hartmann, P.;van Lunzen, J. et al. Relevance of the organic cation transporters 1and 2 for antiretroviral drug therapy in human immunodeficiencyvirus infection. Drug Metab Dispos., 2008, 36(8), 1616-1623.
166. Zhang, L.; Dresser, M.J.; Gray, A.T.; Yost, S.C.; Terashita, S.;Giacomini, K.M. Cloning and functional expression of a humanliver organic cation transporter. Mol. Pharmacol., 1997, 51(6), 913-921. (Pubitemid 27249124)
167. Tamai, I.; Yabuuchi, H.; Nezu, J.; Sai, Y.; Oku, A.; Shimane, M. etal. Cloning and characterization of a novel human pH-dependentorganic cation transporter, OCTN1. FEBS Lett., 1997, 419(1), 107-111. (Pubitemid 28011227)
168. McBride, B.F.; Yang, T.; Liu, K.; Urban, T.J.; Giacomini, K.M.;Kim, R.B. et al. The organic cation transporter, OCTN1, expressedin the human heart, potentiates antagonism of the HERG potassiumchannel. J. Cardiovasc. Pharmacol., 2009, 54(1), 63-71.
169. Glaeser, H.; Bailey, D.G.; Dresser, G.K.; Gregor, J.C.; Schwarz,U.I.; McGrath, J.S. et al. Intestinal drug transporter expression andthe impact of grapefruit juice in humans. Clin. Pharmacol. Ther.,2007, 81(3), 362-370. (Pubitemid 46364477)
170. Tamai, I.; Ohashi, R.; Nezu, J.; Yabuuchi, H.; Oku, A.; Shimane,M. et al. Molecular and functional identification of sodium iondependent,high affinity human carnitine transporter OCTN2. J.Biol. Chem., 1998, 273(32), 20378-20382. (Pubitemid 28377603)
171. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Hosoyamada,M.; Cha, S.H. et al. Characterization of methotrexate transportand its drug interactions with human organic anion transporters.J. Pharmacol. Exp. Ther., 2002, 302(2), 666-671. (Pubitemid 34787234)
172. Cihlar, T.; Lin, D.C.; Pritchard, J.B.; Fuller, M.D.; Mendel, D.B.;Sweet, D.H. The antiviral nucleotide analogs cidofovir and adefovirare novel substrates for human and rat renal organic aniontransporter 1. Mol. Pharmacol., 1999, 56(3), 570-580. (Pubitemid 29406884)
173. Alebouyeh, M.; Takeda, M.; Onozato, M.L.; Tojo, A.; Noshiro, R.;Hasannejad, H. et al. Expression of human organic anion transportersin the choroid plexus and their interactions with neurotransmittermetabolites. J. Pharmacol. Sci., 2003, 93(4), 430-436. (Pubitemid 38195311)
174. Hosoyamada, M.; Sekine, T.; Kanai, Y.; Endou, H. Molecularcloning and functional expression of a multispecific organic aniontransporter from human kidney. Am. J. Physiol, 1999, 276(1 Pt 2),F122-F128. (Pubitemid 29061732)
175. Enomoto, A.; Takeda, M.; Shimoda, M.; Narikawa, S.; Kobayashi,Y.; Kobayashi, Y. et al. Interaction of human organic anion transporters2 and 4 with organic anion transport inhibitors. J. Pharmacol.Exp. Ther., 2002, 301(3), 797-802. (Pubitemid 34595067)
176. Shin, H.J.; Lee, C.H.; Lee, S.S.; Song, I.S.; Shin, J.G. Identificationof genetic polymorphisms of human OAT1 and OAT2 genes andtheir relationship to hOAT2 expression in human liver. Clin. Chim.Acta, 2010, 411(1-2), 99-105.
177. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Hosoyamada,M.; Cha, S.H. et al. Characterization of methotrexate transportand its drug interactions with human organic anion transporters.J. Pharmacol. Exp. Ther., 2002, 302(2), 666-671. (Pubitemid 34787234)
178. Takeda, M.; Khamdang, S.; Narikawa, S.; Kimura, H.; Hosoyamada,M.; Cha, S.H. et al. Characterization of methotrexate transportand its drug interactions with human organic anion transporters.J. Pharmacol. Exp. Ther., 2002, 302(2), 666-671. (Pubitemid 34787234)
179. Cha, S.H.; Sekine, T.; Kusuhara, H.; Yu, E.; Kim, J.Y.; Kim, D.K.et al. Molecular cloning and characterization of multispecific organicanion transporter 4 expressed in the placenta. J. Biol. Chem.,2000, 275(6), 4507-4512. (Pubitemid 30094696)
180. Babu, E.; Takeda, M.; Narikawa, S.; Kobayashi, Y.; Enomoto, A.;Tojo, A. et al. Role of human organic anion transporter 4 in thetransport of ochratoxin A. Biochim. Biophys. Acta, 2002, 1590(1-3), 64-75. (Pubitemid 34626769)
181. Lee, W.; Glaeser, H.; Smith, L.H.; Roberts, R.L.; Moeckel, G.W.;Gervasini, G. et al. Polymorphisms in human organic aniontransportingpolypeptide 1A2 (OATP1A2): implications for altereddrug disposition and central nervous system drug entry. J. Biol.Chem., 2005, 280(10), 9610-9617. (Pubitemid 40409657)
182. Gao, B.; Hagenbuch, B.; Kullak-Ublick, G.A.; Benke, D.; Aguzzi,A.; Meier, P.J. Organic anion-transporting polypeptides mediatetransport of opioid peptides across blood-brain barrier. J. Pharmacol.Exp. Ther., 2000, 294(1), 73-79. (Pubitemid 30434672)
183. Gao, B.; Huber, R.D.; Wenzel, A.; Vavricka, S.R.; Ismair, M.G.;Reme, C. et al. Localization of organic anion transporting polypeptidesin the rat and human ciliary body epithelium. Exp. Eye Res.,2005, 80(1), 61-72. (Pubitemid 40126514)
184. Polli, J.W.; Humphreys, J.E.; Harmon, K.A.; Castellino, S.;O'Mara, M.J.; Olson, K.L. et al. The role of efflux and uptaketransporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethy l]amino}methyl)-2-furyl]-4-quinazolinamine(GW572016, lapatinib) disposition and drug interactions.Drug Metab Dispos., 2008, 36(4), 695-701. (Pubitemid 351468376)
185. Hsiang, B.; Zhu, Y.; Wang, Z.; Wu, Y.; Sasseville, V.; Yang, W.P.et al. A novel human hepatic organic anion transporting polypeptide(OATP2). Identification of a liver-specific human organic aniontransporting polypeptide and identification of rat and humanhydroxymethylglutaryl-CoA reductase inhibitor transporters. J.Biol. Chem., 1999, 274(52), 37161-37168.
186. Konig, J.; Cui, Y.; Nies, A.T.; Keppler, D. A novel human organicanion transporting polypeptide localized to the basolateral hepatocytemembrane. Am. J. Physiol Gastrointest. Liver Physiol, 2000,278(1), G156-G164. (Pubitemid 30108080)
187. Konig, J.; Cui, Y.; Nies, A.T.; Keppler, D. Localization and genomicorganization of a new hepatocellular organic anion transportingpolypeptide. J. Biol. Chem., 2000, 275(30), 23161-23168. (Pubitemid 30646210)
188. Pizzagalli, F.; Hagenbuch, B.; Stieger, B.; Klenk, U.; Folkers, G.;Meier, P.J. Identification of a novel human organic anion transportingpolypeptide as a high affinity thyroxine transporter. Mol. Endocrinol.,2002, 16(10), 2283-2296. (Pubitemid 35155540)
189. Lu, R.; Kanai, N.; Bao, Y.; Schuster, V.L. Cloning, in vitro expression,and tissue distribution of a human prostaglandin transportercDNA(hPGT). J. Clin. Invest, 1996, 98(5), 1142-1149. (Pubitemid 26299927)
190. Schuster, V.L.; Lu, R.; Coca-Prados, M. The prostaglandin transporteris widely expressed in ocular tissues. Surv. Ophthalmol.,1997, 41 Suppl 2, S41-S45. (Pubitemid 27154523)
191. Pizzagalli, F.; Varga, Z.; Huber, R.D.; Folkers, G.; Meier, P.J.; StPierre, M.V. Identification of steroid sulfate transport processes inthe human mammary gland. J. Clin. Endocrinol. Metab, 2003,88(8), 3902-3912. (Pubitemid 37034545)
192. Englund, G.; Rorsman, F.; Ronnblom, A.; Karlbom, U.; Lazorova,L.; Grasjo, J. et al. Regional levels of drug transporters along thehuman intestinal tract: co-expression of ABC and SLC transportersand comparison with Caco-2 cells. Eur. J. Pharm. Sci., 2006, 29(3-4), 269-277. (Pubitemid 44602404)
193. Meier, Y.; Eloranta, J.J.; Darimont, J.; Ismair, M.G.; Hiller, C.;Fried, M. et al. Regional distribution of solute carrier mRNA expressionalong the human intestinal tract. Drug Metab Dispos.,2007, 35(4), 590-594. (Pubitemid 46513261)
194. Kullak-Ublick, G.A.; Ismair, M.G.; Stieger, B.; Landmann, L.;Huber, R.; Pizzagalli, F. et al. Organic anion-transporting polypeptideB (OATP-B) and its functional comparison with three otherOATPs of human liver. Gastroenterology, 2001, 120(2), 525-533. (Pubitemid 32147650)
195. Schiffer, R.; Neis, M.; Holler, D.; Rodriguez, F.; Geier, A.; Gartung,C. et al. Active influx transport is mediated by members ofthe organic anion transporting polypeptide family in human epidermalkeratinocytes. J. Invest Dermatol., 2003, 120(2), 285-291. (Pubitemid 36513079)
196. Kobayashi, D.; Nozawa, T.; Imai, K.; Nezu, J.; Tsuji, A.; Tamai, I.Involvement of human organic anion transporting polypeptideOATP-B (SLC21A9) in pH-dependent transport across intestinalapical membrane. J. Pharmacol. Exp. Ther., 2003, 306(2), 703-708. (Pubitemid 36886171)
197. Huber, R.D.; Gao, B.; Sidler Pfandler, M.A.; Zhang-Fu, W.;Leuthold, S.; Hagenbuch, B. et al. Characterization of two splicevariants of human organic anion transporting polypeptide 3A1 isolatedfrom human brain. Am. J. Physiol Cell Physiol, 2007, 292(2),C795-C806.
198. Tamai, I.; Nezu, J.; Uchino, H.; Sai, Y.; Oku, A.; Shimane, M. etal. Molecular identification and characterization of novel membersof the human organic anion transporter (OATP) family. Biochem.Biophys. Res. Commun., 2000, 273(1), 251-260. (Pubitemid 30426895)
199. Adachi, H.; Suzuki, T.; Abe, M.; Asano, N.; Mizutamari, H.;Tanemoto, M. et al. Molecular characterization of human and ratorganic anion transporter OATP-D. Am. J. Physiol Renal Physiol,2003, 285(6), F1188-F1197. (Pubitemid 37421055)
200. Sato, K.; Sugawara, J.; Sato, T.; Mizutamari, H.; Suzuki, T.; Ito, A.et al. Expression of organic anion transporting polypeptide E(OATP-E) in human placenta. Placenta, 2003, 24(2-3), 144-148. (Pubitemid 37184709)
201. Lee, S.Y.; Williamson, B.; Caballero, O.L.; Chen, Y.T.; Scanlan,M.J.; Ritter, G. et al. Identification of the gonad-specific aniontransporter SLCO6A1 as a cancer/testis (CT) antigen expressed inhuman lung cancer. Cancer Immun., 2004, 4, 13.
202. Suzuki, T.; Onogawa, T.; Asano, N.; Mizutamari, H.; Mikkaichi,T.; Tanemoto, M. et al. Identification and characterization of novelrat and human gonad-specific organic anion transporters. Mol. Endocrinol.,2003, 17(7), 1203-1215. (Pubitemid 36819945)
203. Bleasby, K.; Castle, J.C.; Roberts, C.J.; Cheng, C.; Bailey, W.J.;Sina, J.F. et al. Expression profiles of 50 xenobiotic transportergenes in humans and pre-clinical species: a resource for investigationsinto drug disposition. Xenobiotica, 2006, 36(10-11), 963-988. (Pubitemid 44844110)
204. Hilgendorf, C.; Ahlin, G.; Seithel, A.; Artursson, P.; Ungell, A.L.;Karlsson, J. Expression of thirty-six drug transporter genes in humanintestine, liver, kidney, and organotypic cell lines. Drug MetabDispos., 2007, 35(8), 1333-1340. (Pubitemid 47121774)